Compare CBIO & SVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBIO | SVC |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Real Estate Investment Trusts |
| Sector | | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 389.7M | 361.4M |
| IPO Year | N/A | 1995 |
| Metric | CBIO | SVC |
|---|---|---|
| Price | $11.31 | $2.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $26.67 | $2.50 |
| AVG Volume (30 Days) | 200.5K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.77% |
| EPS Growth | N/A | ★ 26.95 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,814,838,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.72 | $1.55 |
| 52 Week High | $17.39 | $3.08 |
| Indicator | CBIO | SVC |
|---|---|---|
| Relative Strength Index (RSI) | 51.39 | 60.26 |
| Support Level | $10.40 | $2.22 |
| Resistance Level | $13.37 | $2.42 |
| Average True Range (ATR) | 0.95 | 0.10 |
| MACD | 0.11 | 0.00 |
| Stochastic Oscillator | 53.64 | 69.70 |
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Service Properties Trust is a real estate investment trust that owns hotel properties. These properties are located in the United States, along with Canada and Puerto Rico. The company operates through its hotel investment unit and net lease investments. The firm derives the majority of its revenue from the hotel real estate investments unit. The hotels are distinguished between their service levels, which include full service, select service, and extended stay; and chain scale, which includes luxury, upper upscale, upscale, upper midscale, and midscale. The hotels are extended stay or upscale. Some of the hotel brands include Courtyard by Marriott, Royal Sonesta, Crowne Plaza Hotels & Resorts, and Hyatt Place.